The possibility of myopathy, especially with statin-fibrate combinations, has prevented health care professionals from more aggressive risk assessment of combination dyslipidemia, such as atherogenic or diabetic dyslipidemia, and initiating combination drug therapy.
A substantial challenge lies in the assessment of combination effects from large numbers of endocrine disrupters and other chemicals, all at low doses.
Furthermore, an integral procedure of non-probabilistic time-dependent reliability assessment by combination of the interval mathematics and the first-passage theory is proposed, and with the help of the regularization treatment, its solution strategy is mathematically conducted as well.
In contrast, the assessment of combination effects has a long tradition in pharmacology, where mixtures of chemicals are specifically designed to develop new products, e.g. human and veterinary drugs or agricultural and non-agricultural pesticides.
In this perspective, DeHCA optical image processing may play a role in breast assessment in combination with US, although the additional diagnostic contribution of DeHCA optical image processing to that of US alone deserves further investigation.
This assessment requires combination of integrated activity in source regions and of the so-called S values that relate mean absorbed dose in an arbitrary region to integrated activity in source regions [3, 4].
At this interim safety assessment, the combination of pertuzumab, trastuzumab and chemotherapy was well tolerated.
These questions address key domains (eg. comprehensive search, validity assessment, results combination) of methodological quality.
We consider both reference models as useful tools for the assessment of combination effects of multiple mixtures of xenoestrogens.
As such, QBA has substantial potential to aid animal welfare assessment, in combination with other approaches, whether as part of experimental studies or on-farm welfare assessment.
